Table 1.
The baseline characteristics of patients.
| Characteristics | Total (N = 67) N (%) |
|---|---|
| Age (years) | |
| Median (range) | 61.4 (33–84) |
| <65 | 44 (65.7) |
| ≥65 | 23 (34.3) |
| Sex | |
| Male | 44 (65.7) |
| Female | 23 (34.3) |
| ECOG PS | |
| 0–1 | 47 (70.1) |
| 2 | 20 (29.9) |
| Tumor stage | |
| Locally advanced | 21 (31.3) |
| Metastatic | 46 (68.7) |
| Treatment line | |
| First | 25 (37.3) |
| ≥Second | 42 (62.7) |
| Baseline CA19–9 (U/ml) | |
| ≤37 | 13 (19.4) |
| >37 | 54 (80.6) |
| TMB (muts/Mb) | |
| <10 | 63 (94.0) |
| ≥10 | 4 (6.0) |
| MSI status | |
| MSI-H | 1 (1.5) |
| MSS | 66 (98.5) |
| PD-L1 expression | |
| CPS≥1 | 3 (4.5) |
| CPS<1 | 64 (95.5) |
| Liver metastasis | |
| Yes | 36 (53.7) |
| No | 31 (46.3) |
| With radiotherapy | |
| Yes | 26 (38.8) |
| No | 41 (61.2) |
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; CA19–9, carbohydrate antigen 19–9; TMB, tumor mutational burden; MSI, microsatellite instability; MSI-H, microsatellite instability-High; MSS, microsatellite stable; PD-L1, programmed death-ligand 1; CPS, combined positive score.